Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

1. Primary Objectives During Phase I study - Determine the safety and maximum tolerated
radiation dose for five fraction SABR for squamous cell cancer of the lung.

During Phase II study - Determine 2 year local control of dose escalated five fraction
SABR vs. institutional historical control standard dose SABR in squamous cell cancer of
the lung.

2. Phase II Secondary Objectives

- Determine overall survival, progression free survival and patterns of failure after
SABR.

- Determine tolerability of dose escalated SABR.

Inclusion Criteria

1. Age ≥ 18 at time of consent.

2. Ability to provide written informed consent and HIPAA authorization.

3. Pathological diagnosis of squamous cell carcinoma of the lung.

4. Staging PET/CT (invasive mediastinal staging strongly encouraged but not required).

5. Tumors < 7cm

6. N0 M0 disease

7. Baseline PFTs available or will be obtained prior to treatment start

Exclusion Criteria

1. Previous radiation therapy to the lung per investigator discretion.

2. Inability to comply with treatment per investigator discretion.

3. Inability to follow standard of care follow up recommendations per investigator
discretion.